← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Hayden Michael R
Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001352908
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 3
- Purchases · 24M
- 5
- Average purchase
- $553.8K
- Median purchase
- $481.0K
- Gross purchase value
- $2.8M
Companies: AbCellera Biologics Inc. | IONIS PHARMACEUTICALS INC
5 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-24 | AbCellera Biologics Inc. | ABCL | Director | $570.4K | Open filing |
| 2026-08-14 | AbCellera Biologics Inc. | ABCL | Director | $481.0K | Open filing |
| 2026-07-31 | IONIS PHARMACEUTICALS INC | IONS | Director | $1.1M | Open filing |
| 2025-05-02 | IONIS PHARMACEUTICALS INC | IONS | Director | $477.9K | Open filing |
| 2024-12-26 | IONIS PHARMACEUTICALS INC | IONS | Director | $181.1K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 40.0% (2/5) | 100.0% (2/2) | +4.3% | +4.3% | +0.8% |
| 20D | 2Small Sample | 40.0% (2/5) | 100.0% (2/2) | +8.9% | +8.9% | +0.1% |
| 60D | 0No Data | 0.0% (0/2) | — | — | — | — |
| 120D | 0No Data | 0.0% (0/2) | — | — | — | — |
Research patterns
- First purchase in 12M
- 2/4
- Large purchase ≥ $100k
- 5/5
- Cluster buying · 15D
- 2/5
- Buying the dip
- 0/2
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.